Kiniksa Pharmaceuticals (NASDAQ: KNSA) Reports Q2 2026 Financial Results and Recent Portfolio Execution on Tuesday July 28, 2026 With ARCALYST (Rilonacept) IL-1α and IL-1β Cytokine Trap Fusion Protein Net Product Revenue of $243.6 Million (+55% Year-Over-Year) for the Approved Recurrent Pericarditis Indication and Positive Phase 2 Data From the KPL-387 Program Showing Rapid and Sustained Reductions in Pain and Inflammation at the 300 mg Once-Monthly Subcutaneous Injection Dose; Kiniksa Hosted an 8:30 AM Eastern Time Conference Call to Discuss Q2 Financial Performance and Portfolio Pipeline Advancement
Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported Q2 2026 financial results Tuesday July 28, 2026 with ARCALYST (rilonacept, an IL-1α and IL-1β cytokine trap fusion protein) net product revenue of $243.6 million, +55% year-over-year growth. ARCALYST is FDA-approved for the reduction in risk of recurrence of pericarditis in patients 12 years of age and older, and represents Kiniksa's primary commercial franchise. The Q2 revenue trajectory reflects continued cardiovascular-specialist adoption of rilonacept as a maintenance therapy alternative to colchicine-plus-corticosteroid regimens in the recurrent pericarditis population. Kiniksa separately reported Phase 2 data from the KPL-387 program (an investigational IL-1 receptor antagonist monoclonal antibody) showing rapid and sustained reductions in pain and inflammation at the 300 mg subcutaneous injection administered once monthly. The company hosted a conference call and webcast at 8:30 AM Eastern Time Tuesday July 28 to discuss Q2 financial performance and portfolio pipeline advancement including KPL-387 next-step development, ARCALYST commercial expansion, and additional pipeline candidates. Kiniksa Pharmaceuticals is one of the peptide-adjacent biotech companies focused on IL-1 pathway inhibition through both antibody and fusion-protein modalities.